concurrent remdesivir (Gilead Sciences)
99
Structured Review
Gilead Sciences
concurrent remdesivir
Concurrent Remdesivir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15565 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/concurrent+remdesivir/VEKLURY/pmc10716356-186-22-23
Average 99 stars, based on 15565 article reviews
Concurrent Remdesivir, supplied by Gilead Sciences, used in various techniques. Bioz Stars score: 99/100, based on 15565 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/concurrent+remdesivir/VEKLURY/pmc10716356-186-22-23
Average 99 stars, based on 15565 article reviews
concurrent remdesivir - by Bioz Stars,
2026-10
99/100 stars
Images
1) Product Images from "Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study"
Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study
Journal: Frontiers in Microbiology
doi: 10.3389/fmicb.2023.1296558
Figure Legend Snippet: TTFields application together with remdesivir is beneficial in vitro . TTFields were applied for 48 h, alone or concomitantly with 0.011 or 0.023 μM remdesivir, to MRC-5 cells that were infected during the first 3 h of treatment with HCoV-229E (MOI = 0.01). The intracellular viral amount was examined by RT-qPCR (A) and by fluorescence detection of dsRNA with green staining, and cellular nuclei imaged with blue DAPI (x20 magnification) (B) , and the extracellular viral amount was examined by RT-qPCR (C) . MOI, multiplicity of infection; dsRNA, double stranded RNA; RQ, relative quantification. Values are mean ± SD. ** p < 0.01, *** p < 0.001, and **** p < 0.0001 relative to control; Sidak’s multiple comparison.
Techniques Used: In Vitro, Infection, Quantitative RT-PCR, Fluorescence, Staining, Comparison
Figure Legend Snippet: Baseline characteristics and treatment details.
Techniques Used:
Figure Legend Snippet: Effectiveness endpoints.
Techniques Used:
![Ordinal score for clinical improvement (OSCI) at specific time points, no. (%, [95% CI]).](https://pub-med-central-html-table-images-cdn.bioz.com/pub_med_central_ids_ending_with_6356/pmc10716356/pmc10716356__tab5__concurrent_ascii32_remdesivir__gilead_ascii32_sciences.jpg "Ordinal score for clinical improvement (OSCI) at specific time points, no. (%, [95% ...")
Figure Legend Snippet: Ordinal score for clinical improvement (OSCI) at specific time points, no. (%, [95% CI]).
Techniques Used:
Related Articles
In Vitro:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave Infection:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave Quantitative RT-PCR:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave Fluorescence:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave Staining:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave Comparison:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave Coagulation:Article Title: Dexamethasone in hospitalised coronavirus-19 patients not on intensive respiratory support Article Snippet: Article Title: Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro , and safety for application to COVID-19 patients in a pilot clinical study Article Snippet: Treatment duration and usage were higher for patients treated with TTFields alone (4 days and 67.2%, respectively) relative to patients treated with Article Title: Early initiation of corticosteroids in patients hospitalized with COVID-19 not requiring intensive respiratory support: cohort study Article Snippet: Concurrent remdesivir and prophylactic anticoagulants were more common in those who received Article Title: Case Series of Patients with Coronavirus Disease 2019 Pneumonia Treated with Hydroxychloroquine Article Snippet: Of the 27 patients, 18 (66%) received concurrent AZM, 8 (30%) received a concurrent corticosteroid, 3 (11%) received concurrent favipiravir, 2 (7%) received concurrent lopinavir and ritonavir, 2 (7%) received concurrent tocilizumab, and 1 (4%) received Article Title: JAK -inhibitors for coronavirus disease-2019 (COVID-19): a meta-analysis Article Snippet: Fifth, one large study gave |